1-es típusú cukorbetegség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 21
• SGLT2 12
• NRF2 0
• CTLA-4 0
• STAT3 0
• AKT 0
• GIP 2
• PD-1 0
• SIRT1 0
• CD40 0
• PPAR 0
• TP53 0
• JAK 1
• JNK 0
• mTOR 0
• NLRP3 1
• TLR4 0
• AMPK 0
• DPP-4 0
• IL-6 0
• TNF 0
• IL-1 0
• IL-17 0
• MAPK 0
• PI3K 0
• VEGF 1
• CD47 0
• HMGB1 0
• PD-L1 0
• ACE2 0
• BDNF 0
• CD19 0
• CD20 1
• CD38 0
• ERK 0
• FOXP3 0
• G6PD 0
• IL-13 0
• IL-4 0
• PCSK9 0
• RANKL 0
• STING 0
• TIGIT 0
• AR 0
• B7-H3 0
• CD22 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• GPX4 0
• HDAC 0
• HER2 0
• HER3 0
• HSP90 0
• IGF1R 0
• LAG-3 0
• METTL3 0
• MYC 0
• NMDA 0
• PDGFR 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIBIB · DP2

  Decoding Cell-Fate Decisions Through Molecular Recording

  Sloan-Kettering Inst Can Research· New York, Egyesült Államok· 843 125 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NIDDK · F30

  Establishing the Cholinergic Anti-Inflammatory Pathway in Pancreatic Islets.

  University of Miami School of Medicine· Coral Gables, Egyesült Államok· 55 114 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NCCIH · R21

  Probiotic-derived SH3b domains as effector molecules

  University of Florida· Gainesville, Egyesült Államok· 397 502 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIDDK · U01

  Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report

  Healthpartners Institute· Bloomington, Egyesült Államok· 1 542 828 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAID · R01

  Combined engineering of human stem cell-derived beta cells and regulatory T cells to treat type 1 diabetes

  Medical University of South Carolina· Charleston, Egyesült Államok· 640 131 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Modeling islet inflammation in early-stage type 1 diabetes: T1DstartEd (T1Dstarted)

  The Hebrew University of Jerusalem· Jerusalem, Izrael· EU contribution 2 796 250 EUR· until 2032. máj.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  The Inreda bi-hormonal blood glucose control pump: A beacon for high-risk diabetes patients, providing fully automated in disease management (DIABEACON)

  Inreda Diabetic Bv· Goor, Hollandia· EU contribution 2 499 414 EUR· until 2028. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Type 1 Diabetes Simulator with Adjunctive therapies - GLP1 (T1SIA)

  Universitat Politecnica de Valencia· Valencia, Spanyolország· EU contribution 243 097 EUR· until 2028. jan.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  From harassing to harnessing beta-cells in type 1 diabetes (Beta-STEALTH)

  Academisch Ziekenhuis Leiden· Leiden, Hollandia· EU contribution 2 500 000 EUR· until 2030. okt.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Uncovering Protective Mechanisms in Pancreatic β-Cells to Enhance Their Survival in Type 1 Diabetes (Beta_cell_protection)

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution 200 400 EUR· until 2027. júl.

10 of 636 running projects, newest first. Listed amounts together: 464,3 M USD + 48,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 10
• Organoids 4
• Mendelian Randomization Analysis 35
• CRISPR-Cas Systems 5
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 12
• Immunohistochemistry 16
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 33
• Machine Learning 31
• Deep Learning 10
• Cohort Studies 158
• Genome-Wide Association Study 54

• Transcriptional and phenotypic alterations of regulatory and effector T cells in type 1 diabetes mellitus.

  Mol Biomed, 2026. okt.

• Single-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.

  Clin Rev Allergy Immunol, 2026. okt.

• CD180-Associated B-Cell Alterations in Type 1 Diabetes and the In Vitro Effects of Chlorogenic Acid: An Integrated Transcriptomic and Experimental Study.

  Int J Mol Sci, 2026. okt.

• Exploratory bioinformatics analysis for identifying candidate biomarkers of type 1 diabetes mellitus.

  PeerJ, 2026. aug.

• ZBTB16-associated NK cell alterations reveal shared immunometabolic signatures linking primary Sjögren's syndrome and type 1 diabetes mellitus.

  Front Immunol, 2026. aug.

• Diabetic Hyperglycemia Induces Region-Specific Transcriptomic Remodeling in the Cochlea.

  Genes (Basel), 2026. júl.

• Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses.

  Diabetologia, 2026. júl.

• GutMGene-Guided Peripheral Blood Transcriptomics Identifies an FLNA-Associated Host-Gene Signal in Diabetic Retinopathy.

  Int J Mol Sci, 2026. júl.

• Transcriptomics of type 1 diabetes progression: a validation study in newly diagnosed patients.

  EBioMedicine, 2026. júl.

• Molecular mechanisms of erectile dysfunction in type 1 and type 2 diabetic rats: a multiomics approach.

  Asian J Androl, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.